Announcements Trials

Browse Landscape

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Neuroendocrine Tumors 1

Interventions

lutetium Lu 177 dotatate 28 Magnetic Resonance Spectroscopy 15 Everolimus 10 pembrolizumab 9 Specimen Handling 9 cabozantinib 7 Nivolumab 7 Lutetium-177 6 surufatinib 5 lenvatinib 5 Octreotide 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 lanreotide 4 gallium Ga 68 dotatate 4 amino-acid, glucose, and electrolyte solution 4 X-Rays 4 Lutetium 4 Ipilimumab 4 Injections 4 Fluorodeoxyglucose F18 4 Capecitabine 4 olaparib 3 copper dotatate CU-64 3 atezolizumab 3 Temozolomide 3 Cyclophosphamide 3 Carboplatin 3 pasireotide 2 fludarabine phosphate 2 fludarabine 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Engineering × NET × 1 year × Clear all

NCT07366658 2026-01-26

NEUK203-13

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 1 Not yet recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡